How molecular medicine transforms policy (and everything else).
Molecular medicine (also known as pharmacogenomics, pharmacogenetics, gene-based medicine, personalized medicine), after being heralded prematurely as the next revolution in medicine, is in the process now of becoming the first big change in healthcare of the 21st century. Because its scientific, clinical, ethical, financial, and regulatory implications are so far-reaching, it is important to define who and what will be affected in order to put the right societal systems and policies in place to cope with the change. Leaders of the personalized medicine field will be those organizations that see the wave and prepare to adjust their traditional planning, relationships, attitudes and management approach.
Feinstein Kean Healthcare, Cambridge, Massachusetts, USA.
Marcia A
MA
Kean
Keith F
KF
Batchelder
D003695:Delivery of Health Care / Q000191:economics / Q000639:trends; D004345:Drug Industry / Q000639:trends; D008967:Molecular Biology / Q000639:trends; D010597:Pharmacogenetics / Q000191:economics / Q000639:trends*; D011640:Public Policy; D014481:United States; D014486:United States Food and Drug Administration